

Fast relief from dry eyes

Available from Symbion, Sigma and API

Always read the label. Follow the directions for use.

Hydrates
Protects
Restores

Petrus

Today's issue of PD

Pharmacy Daily today features three pages of news, including our **Beauty & Wellness** feature, plus the **April MIMS Monthly Update**, and full pages from:

- Pharmacy Choice
- Glucojel

Freedom to be you

PHARMACY Choice provides banner-level support, buying power and marketing, while allowing full independence - see **page four** for more.

Enjoy your Easter

THERE will be no issue of *Pharmacy Daily* tomorrow or on Mon 06 Apr due to the Easter public holidays.

PD wishes all our readers a safe and enjoyable break, and we look forward to seeing you again on Tue 07 Apr.

Medik8 Physical sunscreen recall

THE Therapeutic Goods Administration has announced that AC Newco is recalling all unexpired batches of Medik8 Physical Sunscreen SPF50+ 60ml, 60ml Professional and 15ml, due to the product being unlikely to meet its labelled SPF rating.

Learn more **HERE**.

Vax coverage decline continues

NEW data from the National Centre for Immunisation Research and Surveillance (NCIRS) has shown continued decrease in childhood vaccination coverage and declining uptake of human papillomavirus (HPV) and meningococcal vaccination in adolescents.

In 2025, fully vaccinated coverage in children fell from 2020 levels to 90.5% at 12 months, 88.4% at 24 months and 92.5% at 60 months of age.

Meanwhile, there has been a global resurgence of measles and pertussis (whooping cough) cases, with higher rates of disease notifications in Australia since 2024.

"These data highlight a growing number of missed or delayed vaccinations across multiple age groups, meaning year on year, tens of thousands of young children are without protection against diseases that we know are still a real and serious risk," said NCIRS director Professor Kristine Macartney.

Older adult vaccination coverage generally continued to climb in 2025 but was still relatively low, with pneumococcal vaccination in people aged 70 years and above at only 48.0%.

Vaccination rates among Aboriginal and Torres Strait Islander children and adolescents also declined over the years since 2020, and while childhood vaccination rates compared favourably overall to the general population, meningococcal and HPV vaccination rates were lower.

With missed childhood vaccinations now driven more by



beliefs and concerns about vaccines than access issues, such as booking vaccination appointments and costs (**PD** 19 Feb), Professor Macartney emphasised the importance of working collaboratively with key stakeholders to address the issues.

"It is now time to strengthen coordination and implementation of key actions - including community-led outreach, expanded support for trusted provider conversations, more transparent and actionable data, and convenient, client-focused immunisation services - to restore confidence, close equity gaps and protect Australians from these awful and entirely preventable diseases into the future," Professor Macartney concluded.

In response to the report, PSA vaccination ambassador Anna Theophilos highlighted the need for national consistency in access to vaccines, scope of practice, funding pathways and age eligibility to improve vaccination coverage, with the current variation by state creating confusion for pharmacists, patients and the broader health system.

"If we truly want to lift coverage and prevent avoidable outbreaks, we need to remove all barriers," Theophilos said.

"All ages. All vaccines. All states." Read the report **HERE**. *KB*

Glucojel glucofest

GLUCOJEL is giving customers the chance to win a year's supply of their favourite Glucojel products.

Order your free POS now - for more details see **page five**.

NOT JUST FLU. THERE'S WHOOPING COUGH TOO

Ask about a **DOUBLE SHOT**
Help prevent whooping cough as well as the flu!

1. Australian Government. Department of Health, Disability and Ageing. Australian Immunisation Handbook. Available at <https://immunisationhandbook.health.gov.au>. Accessed March 2026.
sanofi-aventis australia pty ltd trading as Sanofi. All rights reserved. ABN 31 008 558 807. Sydney, Australia. www.sanofi.com.au. MAT-AU-2600393 V1. Date of preparation: March 2026.

sanofi

chemist posdirect
Your IT Solutions Partner

IS YOUR PHARMACY A CYBER TARGET?

Healthcare has been Australia's most breached sector for years running. Pharmacies hold exactly what cybercriminals want.

Take our free 3-minute Pharmacy Cyber Risk Assessment and find out where your risks are.

Free Risk Assessment

worx
by Escipient

Real time control of your dispensary.

LEARN MORE
medview.com.au/worx

- Triage
- Prioritise
- Track

Editor's Choice: Nominees for Best New Beauty Awards released

BEAUTY website Beautyheaven has released the nominees for its Best New Beauty Awards as voted by readers, including products from well-loved pharmacy brands.

One of the nominees is The Jojoba Company Neck & Decolletage Lifting Concentrate.

According to one reader, the product has "quickly become a staple in my skincare routine".

Burt's Bees Rescue Lip Relief also made the list, formulated with beeswax, shea and echinacea to instantly relieve and hydrate severely dry, chapped lips.

Another nominee was No7 Future Renew Repair Night Serum,



which works to repair visible signs of skin damage overnight.

"This serum is powered by No7's Active Peptidology blend, designed to targets the five key signs of skin damage," said Emma Allcock from Beautyheaven.

"The nourishing nighttime serum has a silky, dermatologically-approved formula that will leave your skin feeling softer and more hydrated from the very first use."

Voting closes 13 April.

Estee Lauder acquisition



BEAUTY giant Estee Lauder has officially acquired its remaining interest in Indian beauty brand Forest Essentials, building on its existing 18-year partnership.

One of the top-ranked prestige skincare brands in India, Forest Essentials puts a luxury spin on traditional Indian Ayurveda beauty practices, with its nearly 200 physical stores and well-crafted formulations.

A statement from the business said the Indian brand will have the chance to take advantage of its global brand-building capabilities, operational expertise and prestige distribution network.

"Together, our ambition is clear: to further strengthen the brand's leadership at home while thoughtfully introducing it to a global audience," Stephane de La Faverie, president and CEO said.

"We are committed to expanding this reach without compromising the integrity, craftsmanship, and cultural soul that define Forest Essentials, and look forward to supporting [founder Mira Kulkarni] and her son Sam in the brand's exciting future."

Top brands revealed

INDUSTRY website Beauty Directory has revealed its top 10 branded search terms for media in Mar, with several pharmacy favourites making the cut.

These included Mavala Switzerland at number four, followed by haircare label Kerastase, while L'Oreal Paris came in at sixth, Lancome at seventh and Weleda at 10th.

New Jergens tanning gel offers natural glow




AMERICAN skincare brand Jergens has released this week the new Natural Glow Hydra Gel Moisturizer (RRP \$16.99) in two shades - fair to medium and medium to deep.

The lightweight face and body sunless tanner promises to offer both a bronze glow as well as skincare benefits.

Formulated with hyaluronic acid, the moisturiser aims to deliver deep hydration to help skin feel soft and renewed.

Easily absorbed, the fragrance-free moisturiser offers hassle-free application, gliding over the skin for a streak-free glow from head to toe.

Jergens' new gel moisturiser is available now in pharmacies around the country.



Want to feature on this page?

email advertising@pharmacydaily.com.au to find out more

Beauty & Wellness
by Pharmacy Daily

Dispensary Corner

A PATIENT in New York took home more than a newborn baby and some high-end loot after giving birth at a luxe hospital renowned for giving away Chanel gift bags - she also took home fleas.

The woman, named Lindsay, had a C-section birth at the NewYork-Presbyterian's Alexandra Cohen Hospital for Women and Newborns.

Lindsay first noticed signs of trouble when she moved into the hospital's private post-partum rooms where she spotted holes in the bedsheets.

This followed with her waking up at 3am with a feeling she compared to "mosquito bites all around her ankles", despite claiming to wear freshly laundered compression socks brought from home.

The itching lasted a few days until it eventually turned into throbbing blisters.

Lindsay said that the itching was so bad, she had to reach down to her ankles to scratch, which is dangerous when recovering from a C-section.

Then after going home, Lindsay, her husband and her newborn child had to evacuate their apartment for fumigators.

To add insult to injury, Lindsay's incision allegedly became infected due to the constant moving.

The hospital is one of the most sought after in New York City for women due to give birth, with Chanel providing the hospital with an endowment in 2004 to give away free goodie bags worth around US\$200 (A\$290).

PSA launches guide for people with autism

THE Pharmaceutical Society of Australia (PSA) has marked World Autism Awareness Day today with a new guide designed to help autistic people better understand how their pharmacist can support their medicine and health needs.

The guide - *Your medicines, your pharmacist* - was supported by a grant from the South Australian Government Office for Autism and developed in partnership with Autism SA, expert pharmacists, and working group members with lived experience of autism, to ensure the guide is optimised for the autistic community.

PSA South Australia and Northern Territory president Adjunct Professor Manya Angley was a key developer of the guide, and highlighted its value in helping autistic people and their families to make the most of the support pharmacists can offer.

"The guide is very close to my heart," Prof Angley said.

"As a family member of an autistic person, I've seen firsthand how important it is for autistic people and their families to feel supported and understood within the healthcare system.

"For decades, I have been advocating for pharmacists to play a bigger role in the care of autistic people," she continued.

"Community pharmacists are highly accessible and can provide vital support, from everyday advice in the pharmacy to more in-depth medication reviews that help ensure medicines are safe, effective, and tailored to individual needs."

The guide covers dose administration aids, medication management review, compounding medicines, the take-home naloxone program and more.

World Autism Awareness Day is marked annually on 02 Apr and aims to "increase the understanding, acceptance, and inclusion of autistic people by promoting autism awareness and emphasising the importance of accessible, supportive services within the community".

Access the guide [HERE](#).



WA introduces world-first RSV initiative

THE Western Australian Government will introduce additional protection against respiratory syncytial virus (RSV) for infants this winter, thanks to an expansion of the state-funded RSV immunisation program.

Effective immediately, all babies born between 01 Oct 2025 and 31 Mar 2026 are eligible to receive nirsevimab (Beyfortus) at no cost ahead of winter - regardless of whether their mother received the RSV vaccine while pregnant.

This world-first measure will provide added protection for thousands of babies born during spring and summer to mothers who received maternal immunisation through the

Federal Government's National Immunisation Program (NIP).

By the time the winter RSV season arrives for these babies, the maternal antibodies passed on during pregnancy will have diminished, leaving the infant with little, if any, protection against severe RSV illness.

"We commend Western Australia for continuing to lead the fight against RSV," said Immunisation Foundation of Australia founder and director, Catherine Hughes.

"Ideally, other state and federal governments should follow WA's lead and offer similar, optimal programs, because no baby should be left unprotected from RSV in the winter season," she added.



1800 429 829
info@ravensrecruitment.com.au
www.ravensrecruitment.com.au

Pharmacist in Charge

Central Highlands, VIC. (Job #49365)


- Leadership role in a well-supported, established pharmacy group.
- Full-time Roster with monthly RDO option.
- \$55-\$62/ph dependant on experience.

Regional lifestyle, affordable living & easy access to Melbourne. An excellent balance between lifestyle & career progression.

[...see more info](#)

Pharmacy[®] Choice

Simply Better.



We Do It For You

We handle buying power, marketing and support services, giving you more time to focus on your pharmacy.



Freedom To Be You

We give you banner-level support, national programs and guidance, while you stay fully independent and true to your own brand.

**Contact us
for more info**

GLUCO FEST!

TASTE THE JOY

WIN THE SWEET LIFE!



TASTE THE JOY, WIN THE SWEET LIFE!

Your customers will have the chance to win a year's supply of their favourite Glucojel products.*

Help us celebrate Glucofest by ordering your campaign POS. And don't forget our Everyday Buying Deal to stock up on Glucojel!

Entries open 20 April 2026.

OUR PROFIT IS YOUR PROFIT.

Visit goldx.com.au/glucojel for more info

*T&C's apply



New Products

- **Fedratinib (as dihydrochloride monohydrate) (Inrebic)** is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase (JAK) 2 and FMS-like tyrosine kinase 3 (FLT3). Fedratinib is a JAK2-selective inhibitor with higher inhibitory activity for JAK2 over family members JAK1, JAK3, and tyrosine kinase 2. Abnormal activation of JAK2 is associated with myeloproliferative neoplasms, including myelofibrosis and polycythaemia vera. In cell models expressing mutationally active JAK2^{V617F} or FLT3^{TD}, fedratinib reduced phosphorylation of signal transducer and activator of transcription (STAT3/5) proteins, inhibited cell proliferation, and induced apoptotic cell death. In mouse models of JAK2^{V617F}-driven myeloproliferative disease, fedratinib blocked phosphorylation of STAT3/5, and improved survival, white blood cell counts, haematocrit, splenomegaly, and fibrosis. *Inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are JAK inhibitor naïve or have been treated with ruxolitinib.* Inrebic capsules contain fedratinib 100 mg and are available in packs of 120.
- **Givosiran (sodium) (Givlaari)** is a double-stranded small interfering ribonucleic acid that causes degradation of aminolevulinic acid synthase 1 (ALAS1) messenger ribonucleic acid (mRNA) in hepatocytes through RNA interference. ALAS1 is the first and rate-limiting enzyme of heme synthesis in the liver. Its expression is induced in acute hepatic porphyria (AHP) due to a loss-of-function gene mutation in a downstream heme synthesis enzyme. Givosiran acts to reduce elevated levels of liver ALAS1 mRNA. This leads to reduced circulating levels of neurotoxic heme intermediates aminolevulinic acid and porphobilinogen, the key causal factors of attacks and other disease manifestations of AHP. *Givlaari is indicated for the treatment of AHP in adults and adolescents aged 12 years and older.* Givlaari solution for injection contains givosiran 189 mg per 1 mL and is available in packs of 1 vial.
- **Influenza virus vaccine, trivalent (live attenuated) (FluMist)** is a trivalent vaccine that contains antigens for three influenza virus strains, an A/(H1N1) strain, an A/(H3N2) strain, and a B strain (Victoria lineage). The influenza virus strains in FluMist are (a) cold-adapted (ca) (i.e. they replicate efficiently at 25°C, a temperature that is restrictive for replication of many wild-type influenza viruses); (b) temperature-sensitive (ts) (i.e. they are restricted in replication at 37°C (Type B strain) or 39°C (Type A strains), temperatures at which many wild-type influenza viruses grow efficiently); and (c) attenuated (att) (i.e. they do not produce classic influenza-like illness in the ferret model of human influenza infection). The cumulative effect of the antigenic properties and the ca, ts, and att phenotypes is that the attenuated vaccine viruses replicate in the nasopharynx and induce protective immunity. Immune mechanisms conferring protection against influenza following receipt of FluMist vaccine are not fully understood. Likewise, naturally acquired immunity to wild-type influenza has not been completely elucidated. Serum antibodies, mucosal antibodies and influenza-specific T cells may play a role in prevention of infection and in recovery from infection. *FluMist is indicated for the prevention of influenza in children and adolescents from 24 months to less than 18 years of age.* FluMist is contraindicated in children and adolescents who have had a severe allergic reaction (e.g. anaphylaxis) to the active substances, any of the excipients (e.g. gelatin, gentamicin (a trace residue), eggs or egg proteins (e.g. ovalbumin); with clinical immunodeficiency due to conditions or immunosuppressive therapy such as acute and chronic leukaemias, lymphoma, symptomatic HIV infection, cellular immune deficiencies, and high-dose corticosteroids; and those receiving salicylate therapy because of the association of Reye's syndrome with salicylates and wild-type influenza infection. FluMist nasal spray contains live attenuated trivalent influenza virus 30 million fluorescent focus units per 0.2 mL and is available in packs of 1 or 10.
- **Mogamulizumab (Poteligeo)** is a defucosylated, humanised immunoglobulin G1 kappa monoclonal antibody that selectively binds to CC chemokine receptor 4 (CCR4), a G protein-coupled receptor for CC chemokines that is involved in the trafficking of lymphocytes to various organs including the skin. CCR4 is expressed on the surface of some T cell malignancies, such as mycosis fungoides (MF) and Sézary syndrome (SS) as well as type 2 T helper T cells and regulatory T cells. Binding of mogamulizumab to CCR4 induces antibody-dependent cellular cytotoxicity, resulting in the depletion of target cells. *Poteligeo is indicated for the treatment of adult patients (≥ 18 years of age) with MF or SS who have received at least one prior systemic therapy.* Poteligeo concentrate for infusion contains mogamulizumab 20 mg per 5 mL and is available in packs of 1 vial.
- **Repotrectinib (Augtyro)** is a tyrosine kinase inhibitor (TKI) that inhibits the proto-oncogene tyrosine-protein kinase ROS1. Fusion proteins containing a ROS1 kinase domain can drive oncogenesis via constitutive activation of downstream signalling pathways and unconstrained cell proliferation. Point mutations within the ROS1 kinase domain, including those affecting the solvent front (e.g. G2032R) or gatekeeper residue (e.g. L2026M), can confer resistance to treatment with TKIs through steric hindrance of drug binding. Repotrectinib is a compact, macrocyclic TKI that binds entirely within the ATP-binding pocket of the kinase domain and lacks structural extensions into the solvent front region. *Augtyro, as monotherapy, is indicated for the treatment of adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer.* Augtyro capsules contain repotrectinib 40 mg or 160 mg and are available in packs of 120 (40 mg) or 60 (160 mg).

New Indications

- **Durvalumab (rch) (Imfinzi)** in combination with FLOT (fluorouracil, leucovorin, oxaliplatin and docetaxel) chemotherapy, as neoadjuvant and adjuvant treatment, followed by adjuvant Imfinzi monotherapy, is now indicated for the treatment of adults with resectable gastric or gastroesophageal junction adenocarcinoma.
- **Selumetinib (sulfate) (Koselugo)** is now also indicated for the treatment of adults with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.